Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 5/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY4R | P50391 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324613 | 0.82 | OPRD1 (0.48) | NTSR1OPRD1NTSR2 | |
| SCHEMBL6324625 | 0.82 | OPRD1 (0.48) | NTSR1OPRD1NTSR2 | |
| SCHEMBL31020747 | 0.82 | CAPN1 (0.48) | NTSR1NTSR2NPY2RNPY4RNPY5R | |
| SCHEMBL30272479 | 0.81 | NTSR1 (0.51) | NTSR1OPRD1NTSR2NPY2RNPY4R | |
| SCHEMBL31433254 | 0.81 | OPRD1 (0.56) | NTSR1MAPK8MAPK9MAPK10OPRD1 | |
| SCHEMBL31196712 | 0.81 | NPY2R (0.53) | NTSR1OPRD1NTSR2NPY2RNPY4R | |
| SCHEMBL30400286 | 0.80 | NTSR1 (0.53) | NTSR1NTSR2NPY2RNPY4RNPY5R | |
| SCHEMBL29387855 | 0.80 | NPY2R (0.56) | NTSR1OPRD1NPY2RNPY4RNPY5R | |
| SCHEMBL30997418 | 0.80 | RAMP3 (0.53) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30930175 | 0.80 | RAMP3 (0.53) | NPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | NTSR1 2090/4885MAPK8 3065/4885MAPK9 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.